SELPERCATINIB - Generic Drug Details

What are the generic sources for selpercatinib and what is the scope of patent protection?

Selpercatinib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in two NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selpercatinib has one hundred and forty-seven patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for SELPERCATINIB

International Patents:	147
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	31
What excipients (inactive ingredients) are in SELPERCATINIB?	SELPERCATINIB excipients list
DailyMed Link:	SELPERCATINIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SELPERCATINIB

Dosage:

CAPSULE;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SELPERCATINIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Oklahoma	EARLY_PHASE1
Presbyterian Health Foundation	EARLY_PHASE1
Fujian Medical University	PHASE4

See all SELPERCATINIB clinical trials

Pharmacology for SELPERCATINIB

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors P-Glycoprotein Inhibitors Rearranged during Transfection (RET) Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SELPERCATINIB

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for SELPERCATINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RETEVMO	Capsules	selpercatinib	40 mg and 80 mg	213246	1	2024-05-08

US Patents and Regulatory Information for SELPERCATINIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-002	Apr 10, 2024		RX	Yes	No
Eli Lilly And Co	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-002	May 8, 2020		RX	Yes	Yes			Y	Y
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-001	Apr 10, 2024		RX	Yes	No
Eli Lilly And Co	RETEVMO	selpercatinib	TABLET;ORAL	218160-004	Apr 10, 2024		RX	Yes	Yes

EU/EMA Drug Approvals for SELPERCATINIB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Retsevmo	selpercatinib	EMEA/H/C/005375Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment	Authorised	no	no	no	2021-02-11

International Patents for SELPERCATINIB

Country	Patent Number	Title	Estimated Expiration
China	118319866	包含RET激酶抑制剂的制剂 (Formulations comprising RET kinase inhibitors)
Israel	273730
Japan	7153719
Mexico	2019004204	COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET. (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.)

Market Dynamics and Financial Trajectory for SELPERCATINIB

Last updated: September 24, 2025

---

Introduction

SELPERCATINIB, a selective RET kinase inhibitor, has garnered significant attention within the pharmaceutical landscape due to its targeted mechanism of action in treating RET-driven cancers, notably certain thyroid and lung cancers. As precision medicine advances, the commercial and financial outlook of SELPERCATINIB hinges on multiple factors—including clinical efficacy, regulatory approval, market competition, and evolving healthcare demands. This comprehensive analysis explores the current market dynamics and forecasts the financial trajectory for SELPERCATINIB from a strategic, investment, and commercial standpoint.

---

Market Dynamics Overview

1. Therapeutic Indication and Market Opportunity

SELPERCATINIB targets RET proto-oncogene mutations, which are implicated in approximately 1-2% of non-small cell lung cancers (NSCLC) and medullary thyroid carcinomas (MTC). The unmet medical need in these niche but high-value markets drives the commercial interest. The global oncology drug market was valued at over USD 225 billion in 2021, with targeted therapies accounting for a substantial share, growing annually at over 12% (1).

The prevalence of RET-positive tumors, while relatively rare, attracts investments due to the high price point typical of oncology drugs. Notably, the estimated treatable population—comprising both NSCLC and thyroid cancers—approximates several thousand patients in key markets like the United States, Europe, and Japan, providing a sizeable niche segment.

2. Competitive Landscape and Differentiation

SELPERCATINIB faces competition from other RET inhibitors such as selpercatinib (Loxo-292, by Eli Lilly) and pralsetinib (Gavreto, by Blueprint Medicines). Both are FDA and EMA-approved and possess demonstrated efficacy, impacting SELPERCATINIB’s market penetration.

Key differentiators for SELPERCATINIB include its selectivity profile, safety, and potential superiority in resistance management. However, until clinical data proves significant advantages over existing options, market share growth remains cautious.

3. Regulatory Milestones and Approvals

Regulatory approval is pivotal. SELPERCATINIB’s trajectory is contingent upon successful Phase III trial outcomes demonstrating non-inferiority or superiority. The FDA’s approval process can take 10-12 months post-submission with NDA filings, with similar timelines in EMA jurisdictions. Accelerated pathways, such as Breakthrough Therapy Designation, can expedite adoption.

A positive and timely approval would catalyze initial sales, notably in the U.S., whereas delays or unfavorable reviews could diminish market potential.

4. Reimbursement and Pricing Dynamics

Oncology drugs are typically premium-priced, especially targeted therapies. Reimbursement policies significantly influence market access and revenue realization. Negotiations with payers will depend on clinical trial data, comparative efficacy, safety profiles, and cost-effectiveness analyses.

In jurisdictions with stringent cost controls, such as some European countries, reimbursement hurdles could temper revenue forecasts.

---

Financial Trajectory

1. Revenue Projections and Growth Drivers

In the initial launch phase, revenues are projected to be modest, reflecting the specialized patient subset and limited geographic coverage. For example, early revenues could range from USD 50-100 million annually in the U.S. within 2–3 years post-approval.

Subsequent growth depends on:

• Market penetration among diagnosed RET-positive patients
• Geographical expansion into Europe and Asia
• Off-label uses or new indications emerging from ongoing trials
• Combination therapies with other oncogenic agents to enhance efficacy

Assuming rapid adoption and favorable pricing, peak annual revenues could reach USD 200-300 million globally within 5-7 years.

2. Cost Considerations and Investment

Investment in clinical trials, regulatory filings, manufacturing scale-up, and commercialization typically entails substantial upfront costs. During early commercialization, gross margins are expected to be around 60-70%, with operating expenses initially high due to marketing and distribution expenses.

Long-term profitability requires operational efficiencies, scalable manufacturing, and competitive pricing strategies.

3. Risk Factors and Market Uncertainties

• Clinical Efficacy Risks: If trial results don’t demonstrate superior efficacy or acceptable safety, market acceptance may falter.
• Regulatory Risks: Delays or rejection can push back revenue realization.
• Competitive Risks: Market dominance hinges on differentiation; any new entrants or generics could erode prices.
• Reimbursement Risks: Payer pushback on pricing could limit patient access and revenue.

---

Strategic Opportunities and Challenges

Opportunities

• Partnering and Licensing: Collaborations with global pharma can accelerate market access.
• Biomarker Development: Refinement of RET mutation detection enhances patient stratification, improving outcomes and market positioning.
• Pipeline Expansion: Investigating additional RET-driven or resistance-related indications offers revenue diversification.

Challenges

• Market Penetration: Competing against established RET inhibitors necessitates demonstrating clear clinical advantages.
• Pricing Pressures: The high-cost nature of targeted oncology drugs might face reimbursement restrictions.
• Regulatory Hurdles: Post-approval surveillance and ongoing efficacy data are vital for sustained market share.

---

Regulatory and Market Outlook

Assuming successful clinical programs and regulatory submissions, the long-term outlook for SELPERCATINIB is cautiously optimistic. The target niche remains financially attractive due to high per-patient treatment costs and unmet medical needs. However, its commercial success depends heavily on early market positioning, clinical data, and competitive dynamics.

---

Key Takeaways

• Market Potential: SELPERCATINIB occupies a niche but lucrative segment within targeted oncology, with an addressable population of several thousand patients globally.
• Growth Drivers: Successful regulatory approval, differentiated clinical benefits, and strategic partnerships will catalyze revenue growth.
• Challenges: Competition, reimbursement negotiations, and clinical uncertainties are primary risks.
• Financial Trajectory: Peak revenues could reach USD 200-300 million annually within 5-7 years, contingent on market adoption.
• Strategic Focus: Emphasis on robust clinical data, cost management, and expanding indications will underpin long-term profitability.

---

FAQs

1. What are the primary indications for SELPERCATINIB?
SELPERCATINIB targets RET-driven cancers, primarily medullary thyroid carcinomas and non-small cell lung cancers with RET mutations or rearrangements.

2. How does SELPERCATINIB compare to existing RET inhibitors?
Its comparative efficacy and safety profiles are under clinical evaluation. Differentiation depends on clinical trial outcomes, with potential advantages in selectivity or resistance management.

3. What are the main barriers to SELPERCATINIB’s market success?
Key challenges include clinical trial success, obtaining regulatory approvals, competitive pressure, and securing favorable reimbursement terms.

4. How large is the global market for RET-targeted therapies?
While relatively niche, the market is valued in the hundreds of millions annually, with growing interest due to advances in precision oncology.

5. What strategic moves can enhance SELPERCATINIB’s financial prospects?
Forming global partnerships, expanding indications, and investing in biomarker-based patient selection can maximize commercial potential.

---

References

1. Grand View Research. "Oncology Drugs Market Size & Share Analysis," 2022.